Cepeginterferon alfa 2b

Drug Profile

Cepeginterferon alfa 2b

Alternative Names: Algeron; Peginterferon alfa 2b - Biocad

Latest Information Update: 02 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biocad
  • Class Antivirals; Interferons; Polyethylene glycols
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 14 May 2014 Biomarkers information updated
  • 01 Dec 2013 Biocad completes a phase II/III trial in Hepatitis C in Russia (NCT01740089)
  • 01 Nov 2013 Phase-III clinical trials in Hepatitis C (Combination therapy, Treatment-naive) in Belarus, Russia and Thailand (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top